By Colin Kellaher
Supernus Pharmaceuticals has won Food and Drug Administration approval for its Onapgo device to treat patients with Parkinson's disease.
Supernus on Tuesday said the FDA green light makes Onapgo the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced forms of the neurodegenerative disorder.
The Rockville, Md., biopharmaceutical company said it plans to make Onapgo available in the second quarter.
Supernus said Onapgo is a wearable infusion device that provides continuous treatment during the waking day for more consistent control of off periods, which can occur in people with Parkinson's disease when there is a return of symptoms in between medication doses.
Shares of Supernus were recently up 5.5% to $39.42.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 04, 2025 10:10 ET (15:10 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.